NASDAQ:THAR Tharimmune (THAR) Stock Price, News & Analysis $2.16 +0.11 (+5.37%) As of 07/21/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Tharimmune Stock (NASDAQ:THAR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tharimmune alerts:Sign Up Key Stats Today's Range$2.02▼$2.1650-Day Range$2.05▼$3.7552-Week Range$0.95▼$9.08Volume681,394 shsAverage Volume1.48 million shsMarket Capitalization$81.50 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey. Read More Tharimmune Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks0th Percentile Overall ScoreTHAR MarketRank™: Tharimmune scored higher than 0% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.5 / 5Analyst RatingSell Consensus RatingTharimmune has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageTharimmune has received no research coverage in the past 90 days.Read more about Tharimmune's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Tharimmune is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tharimmune is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTharimmune has a P/B Ratio of 3.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for THAR. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTharimmune does not currently pay a dividend.Dividend GrowthTharimmune does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Tharimmune this week, compared to 1 article on an average week. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Tharimmune insiders have not sold or bought any company stock.Percentage Held by Insiders6.70% of the stock of Tharimmune is held by insiders.Percentage Held by Institutions1.16% of the stock of Tharimmune is held by institutions.Read more about Tharimmune's insider trading history. Receive THAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tharimmune and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. THAR Stock News HeadlinesTharimmune Inc.May 13, 2026 | wsj.comTharimmune Rebrands as Canton Strategic Holdings, Updates TickerFebruary 18, 2026 | tipranks.comGrab Your First Trade Playbook (link expires)"Your First Trade Playbook" - normally $29.97 - is free to download today. It walks you through every step, from which account to open to which order button to avoid, so you can be ready for your first options trade in a single sitting. The download link expires soon, and the playbook returns to full price once it does.July 22 at 1:00 AM | Profits Run (Ad)Tharimmune, Inc. Announces Corporate Rebrand to Canton Strategic Holdings, Inc., Marking Milestone in Canton Network Digital Asset Treasury StrategyFebruary 17, 2026 | prnewswire.comCatherine Wood's Strategic Moves: A Closer Look at Tesla Inc's Portfolio ImpactFebruary 11, 2026 | finance.yahoo.comTharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating OfficerFebruary 6, 2026 | prnewswire.comTharimmune Elects Jill Sommers and William Wiley to Board of DirectorsFebruary 2, 2026 | prnewswire.comTharimmune Approved as Super Validator on Canton NetworkJanuary 27, 2026 | theglobeandmail.comSee More Headlines THAR Stock Analysis - Frequently Asked Questions How have THAR shares performed this year? Tharimmune's stock was trading at $3.03 at the start of the year. Since then, THAR stock has decreased by 28.7% and is now trading at $2.16. How were Tharimmune's earnings last quarter? Tharimmune, Inc. (NASDAQ:THAR) posted its quarterly earnings data on Thursday, August, 14th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.58) by $0.06. When did Tharimmune's stock split? Shares of Tharimmune reverse split on the morning of Tuesday, May 28th 2024.The 1-15 reverse split was announced on Tuesday, May 28th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 28th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Tharimmune IPO? Tharimmune (THAR) raised $21 million in an IPO on the week of January 10th 2022. The company issued 3,750,000 shares at a price of $5.00-$6.00 per share. How do I buy shares of Tharimmune? Shares of THAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tharimmune own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tharimmune investors own include Jiuzi (JZXN), Avenue Therapeutics (ATXI), Scinai Immunotherapeutics (SCNI), Adial Pharmaceuticals (ADIL), Sphere 3D (ANY), Company Calendar Last Earnings8/14/2025Today7/22/2026Investor update7/22/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:THAR Previous SymbolNASDAQ:THAR CIK1861657 Webwww.hillstreambio.com Phone908-955-3140FaxN/AEmployees2Year FoundedN/AProfitability EPS (Trailing Twelve Months)($3.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.20 million Net MarginsN/A Pretax MarginN/A Return on Equity-588.45% Return on Assets-264.41% Debt Debt-to-Equity RatioN/A Current Ratio4.98 Quick Ratio4.98 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.68 per share Price / Book3.18Miscellaneous Outstanding Shares37,730,000Free Float35,202,000Market Cap$81.50 million OptionableNot Optionable Beta1.43 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:THAR) was last updated on 7/22/2026 by MarketBeat.com Staff. From Our PartnersTwo paths to universal income. One already exists today.Robert Kiyosaki, author of Rich Dad Poor Dad, says there are two paths to Universal Basic Income - wait for El...Freedom Financial | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTSM just handed Trump's secretive AI project $100 billionTaiwan Semiconductor just committed another $100 billion to U.S. chip manufacturing - on top of $165 billion a...InvestorPlace | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredWhite House Insider: “President Trump is Getting Backstabbed!”A high-level White House insider and lifelong friend of the Trump family recently went on camera with a warnin...Paradigm Press | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredElon is about to dominate the biggest arms race in tech historyMicrosoft, Amazon, Alphabet, and Meta have collectively poured nearly $700 billion into AI infrastructure in 2...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tharimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tharimmune With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
